Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists

A pharmaceutical composition comprising a compound according to Formula (III):

• or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein
• R2 is independently selected from CH3 and CD3;
• R13 is independently selected from H and C1-4 alkyl;
• R3 is independently selected from H and C1-4 alkyl;
• R4 is independently selected from C1-6 alkyl substituted with 1-3 R9, —(CR7R7)r-C3-6 cycloalkyl substituted with 1-3 R8, and —(CR7R7)r-aryl substituted with 1-3 R8;
• R5 is independently selected from H, F, Cl, CN and C1-4 alkyl;
• provided one of R5 is H;
• R6 is
• R7 is independently selected from H, C1-4 alkyl, and C3-6 cycloalkyl;
• or R7 and R7, together with the carbon atom to which they both attach, form a C3-6 cycloalkyl ring;
• R8 is independently selected from H, C1-6 alkyl substituted with 1-5 R9, C3-6 cycloalkyl, F, Cl, Br, CN, ═O, and COOH;
• R9 is independently selected from H, F, Cl, NH2, OH, OC1-5alkyl, C1-5alkyl, C3-6 cycloalkyl, and phenyl, wherein when R9 is Cl, NH2 or OH, it is not substituted on C1 of the alkyl to which it is attached;
• R10 is independently selected from H, D, C1-4 alkyl, and F;
• R11 is independently selected from CN, —C(═O)R12, and tetrazolyl;
• R12 is independently selected from OH, OC1-4 alkyl, NH2, and NHSO2C1-4 alkyl;
• and
• r is independently selected from zero, 1, 2, 3, and 4;
• and a pharmaceutically acceptable carrier or diluent.